AMRI, a global contract research, development and manufacturing organization is featuring its complete suite of drug development and manufacturing solutions at Interphex 2018, April 17-19, at the Jacob Javits Center in New York, NY.

Additionally, the company will showcase its container closure integrity testing services offered through its Whitehouse Laboratories division.

“Container closure integrity (CCI) testing plays a critical role the sterility and stability of parenteral products,” said Brandon Zurawlow, associate director, CCIT. “Our technology and unique experience in this space is routinely leveraged at multiple product lifecycle stages including package development, manufacturing process validation, distribution process analysis, and stability programs.”

With the release of the revised USP 1207 and pending Annex 1 revision, the adoption of more modern, deterministic, and comprehensive CCI programs is expanding. AMRI partners with clients to develop container system testing strategies that extend beyond CCI to encompass compendial testing, extractable and leachable studies, ISO device, delivery system testing, among other solutions.

AMRI representatives also will be on-hand at Booth 1129 to discuss the company’s global analytical, API and drug product solutions during the conference.